Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Ernest Awoonor-Williams"'
Autor:
Jacky M. Deng, Salma Elgaili Ahmed, Ernest Awoonor-Williams, Progna Banerjee, Magda H. Barecka, Laura E. Bickerton, Silvina A. Di Pietro, Stanna K. Dorn, Kevin Maik Jablonka, Gabriele Laudadio, Elisabeth Kreidt, Helena Mannochio-Russo, Júlio Terra, Olivia Harper Wilkins, Saigopalakrishna S. Yerneni, Maha Yusuf
Publikováno v:
ACS Central Science, Vol 10, Iss 2, Pp 209-213 (2024)
Externí odkaz:
https://doaj.org/article/4dd91634ade34b1ab28a1869a5fde945
Publikováno v:
Journal of Chemical Information and Modeling. 63:2520-2531
Publikováno v:
Journal of Chemical Information and Modeling. 63:2170-2180
Autor:
Nicholas J. Cundy, Jane Arciszewski, Eric W. J. Gates, Sydney L. Acton, Kyle D. Passley, Ernest Awoonor-Williams, Elizabeth K. Boyd, Nancy Xu, Élise Pierson, Catalina Fernandez-Ansieta, Marie R. Albert, Nicole M. R. McNeil, Gautam Adhikary, Richard L. Eckert, Jeffrey W. Keillor
Publikováno v:
RSC Medicinal Chemistry. 14:378-385
A novel peptidic scaffold was used to design a library of inhibitors that exhibit exceptional efficiency against tissue transglutaminase, providing a framework for the development of potent research tools.
Disruption of the YAP-TEAD protein-protein interaction is an attractive therapeutic strategy for oncology to suppress tumour progression and cancer metastasis. YAP binds to TEAD at a large flat binding interface (~3500 2) devoid of a well-defined dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92d6fc4763a223af6437e1c63b6db398
https://doi.org/10.26434/chemrxiv-2023-px0fb
https://doi.org/10.26434/chemrxiv-2023-px0fb
Autor:
Ernest Awoonor-Williams
Publikováno v:
Physical Chemistry Chemical Physics. 24:23391-23401
Using absolute binding free energy calculations and hybrid QM/MM calculations we estimate the binding energetics of some promising reversible covalent inhibitors of the SARS-CoV-2 main protease, an attractive target for the development of antiviral d
Autor:
Ernest Awoonor-Williams
The main protease (Mpro) of the SARS-CoV-2 virus is an attractive therapeutic target for developing antivirals to combat COVID-19. Mpro is essential for the replication cycle of the SARS-CoV-2 virus, so inhibiting Mpro blocks a vital piece of the cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dd2e075d6df9411226dcf03ac5a59e5
https://doi.org/10.26434/chemrxiv-2021-zpp2j
https://doi.org/10.26434/chemrxiv-2021-zpp2j
Publikováno v:
The Design of Covalent-Based Inhibitors ISBN: 9780128216897
The development of a covalent inhibitor requires the incorporation of an appropriate warhead into the chemical structure of the inhibitor and the selection of an appropriate nucleophilic amino acid to react with the warhead. Prediction of the reactiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee3a9c53d4ebbf8ccaf2ab5c649d68e2
https://doi.org/10.1016/bs.armc.2020.09.001
https://doi.org/10.1016/bs.armc.2020.09.001
COVID-19, the disease caused by the newly discovered coronavirus-SARS-CoV-2, has created a global health, social, and economic crisis. As of mid-January 2021, there are over 90 million confirmed cases and more than 2 million reported deaths due to CO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96df96595fb6fc527fb8c4ea86050fbf
https://doi.org/10.26434/chemrxiv.13288463.v1
https://doi.org/10.26434/chemrxiv.13288463.v1